. . . . " adenoma, squamous cell carcinoma, laryngeal carcinoma, multiple myeloma, melanoma, colorectal cancer, prostate cancer, and proliferative diseases such as restenosis, polycystic kidney disease and any other diseases or conditions that are related to or will respond to the levels of Myc and/or Myb in a cell or tissue, alone or in combination with other therapies." . . .